Abstract

Apixaban 0.25-mg/mL Suspension for Enteral Feeding Tube

Author(s): Allen Loyd V Jr

Issue: Jul/Aug 2021 - Volume 25, Number 4

Page(s): 320

Download in electronic PDF format for $75
  • Apixaban 0.25-mg/mL Suspension for Enteral Feeding Tube Page 1

Abstract

A formulation for preparing Apixaban 0.25-mg/mL Suspension for Enteral Feeding Tube. Includes ingredients, method of preparation, discussion, and references for the compounding pharmacist.

Related Keywords

  • formulation
  • apixaban
  • oral suspension
  • enteral feeding tubes
  • selective factor Xa inhibitor
  • postoperative thromboprophylaxis
  • blood clots
  • deep vein thrombosis
  • pulmonary embolism

Related Categories

  • FORMULATIONS
  • CARDIOLOGY
  • DOSAGE FORMS/DRUG CARRIERS
  • HEMOSTASIS, BLEEDING, ANTICOAGULATION
  • SURGERY

Printer-Friendly Version

Related Articles from IJPC

Issue/Page
View/Buy		 Title/Author
(Click for Abstract / Details / Purchase)
Jul/Aug 2021
Pg. 320
Apixaban 0.25-mg/mL Suspension for Enteral Feeding Tube
Author(s): Allen Loyd V Jr
May/Jun 2022
Pg. 214-217
Basics of Compounding: Vehicle for Drug Administration via Enteral Feeding Tubes
Author(s): Allen Loyd V Jr
May/Jun 2010
Pg. 250-256
Compounding Rifampin Suspensions with Improved Injectability for Nasogastric Enteral Feeding Tube Administration
Author(s): de Villiers Melgardt M, Vogel Laura, Bogenschutz Monica C, Fingerhut Bonnie J, D'Silva Joseph B, Moore Anne
Jul/Aug 2010
Pg. 276-282
Recommendations for Compounding Medications for Feeding Tube Administration
Author(s): Klang Mark
May/Jun 2004
Pg. 181-185
Compounding in the Pharmacy Curriculum: Beyond the Basics
Author(s): Hinkle Amanda R, Newton Gail D
May/Jun 2003
Pg. 206-207
Technology Spotlight: Tube Sealers
Author(s): Jones Michael, Adams Susan
Jul/Aug 2000
Pg. 304
Nasogastric Tube/Percutaneous Endoscopic Gastrostomy Tube Suspension Formula
Author(s): Allen Loyd V Jr
Nov/Dec 2004
Pg. 462-465
Basics of Compounding for Cough
Author(s): Allen Loyd V Jr
Nov/Dec 2016
Pg. 510
Imatinib 40-mg/mL Oral Suspension
Author(s): Allen Loyd V Jr
Sep/Oct 2022
Pg. 358-362
Hazardous Drug Enteral Device: A Closed System Device for Crushing and Dispersing Hazardous Drug Tablets for Enteral Administration
Author(s): Lopez C Vidal, Rios GL Quito
Mar/Apr 2011
Pg. 124-128
Proton Pump Inhibitor Homogenous Suspensions: A Compounding Solution to Pediatric Gastroesophageal Reflux Disease
Author(s): Corsini Lindsay, Williams LaVonn A
Jul/Aug 2021
Pg. 321
Atomoxetine 4-mg/mL Oral Solution/Suspension
Author(s): Allen Loyd V Jr
Nov/Dec 2022
Pg. 446-466
Compounding with Biotechnology Products, Part 2: Product-specific Considerations
Author(s): Allen Loyd V Jr
Sep/Oct 2023
Pg. 420
Nitazoxanide 20-mg/mL Oral Suspension
Author(s): Allen Loyd V Jr
Nov/Dec 2021
Pg. 503
Metoprolol Tartrate 10 mg/mL in SyrSpend SF pH4 Oral Suspension
Author(s): Allen Loyd V Jr
Jul/Aug 2009
Pg. 314-317
Poster Presentation Report: Safety of Maternal Testosterone Therapy During Breast Feeding
Author(s): Glaser Rebecca L, Newman Mark, Parsons Melanie, Zava David, Glaser-Garbrick Daniel
Sep/Oct 2003
Pg. 389-393
Formulation and Accelerated Stability Studies for an Extemporaneous Suspension of Amiodarone Hydrochloride
Author(s): Alexander Kenneth S, Thyangarajapuram N
Jul/Aug 2002
Pg. 255-256
Aminophylline 3%, Co-dergocrine Mesylate 0.05%, and Isosorbide Dinitrate 0.25% Cream for the Treatment of Orgasmic Dysfunction in Women
Author(s): Mason Dave
Jan/Feb 2021
Pg. 43
Amlodipine Besylate 0.5-mg/mL to 10-mg/mL in SuspendIt Oral Suspension
Author(s): Allen Loyd V Jr
Jan/Feb 2021
Pg. 44
Clonidine 0.01-mg/mL in Oral Mix and Oral Mix SF Suspension
Author(s): Allen Loyd V Jr